ClinicalTrials.gg
RecruitingNCT06012240Up-AAUpdated Oct 19, 2026

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Phase 3 interventional study of Upadacitinib and Placebo in Alopecia Areata, sponsored by AbbVie. Recruiting at 272 sites in 28 countries. Open to participants aged 12 Years to 63 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Oct 19, 2026Site recruiting status changed12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
12 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Planned enrollment
Largest of 84
1,500 · median 46
Started
2023
with 8 others
Phase 3
12 of 98
6 open now
Primary completion
2030-04
later than 24 of 31 live
Registered
75th of 98
by date
Lead sponsor
2 of 98
AbbVie

Among the 98 studies in Alopecia Areata with a site in United States, this one has the largest planned enrollment of the 84 interventional ones that give a count, is one of 9 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 24 of the 31 other live ones, and was the 75th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 63 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA.

Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide.

Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Alopecia Areata

Browse trials for

Keywords

  • Alopecia Areata
  • Upadacitinib
  • Rinvoq
  • ABT-494
04

Who can participate

Ages eligible
12 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult individuals must be \< 64 years old at Baseline Visit. Where permitted outside United States (US)/European Union (EU), adolescent individuals who are at least 12 years old at Screening may participate in Study 1 and Study 2. Adolescent individuals in the US who are at least 12 years old at Screening may participate in Study 4.
  • Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score >= 50 scalp hair loss at Screening and Baseline.
  • Severe AA with no spontaneous scalp hair regrowth over the past 6 months.
  • Current episode of AA of less than 8 years.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of primarily diffuse type of AA.
  • Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium.
  • Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Study 1: Group 1 Upadacitinib Dose A

    Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 1: Group 2 Upadacitinib Dose B

    Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 1: Group 3 Placebo

    Participants will receive matching placebo once daily for 24 weeks in Period A.

    Drug: Placebo

  • Experimental
    Study 1: Group 4 Upadacitinib Dose A

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Study 1: Group 5 Upadacitinib Dose B

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Study 1: Group 6 Placebo

    Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.

    Drug: Placebo

  • Experimental
    Study 2: Group 1 Upadacitinib Dose A

    Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 2: Group 2 Upadacitinib Dose B

    Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 2: Group 3 Placebo

    Participants will receive matching placebo once daily for 24 weeks in Period A.

    Drug: Placebo

  • Experimental
    Study 2: Group 4 Upadacitinib Dose A

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Study 2: Group 5 Upadacitinib Dose B

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Study 2: Group 6 Placebo

    Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.

    Drug: Placebo

  • Experimental
    Study 3: Group 1 Upadacitinib Dose B (SALT > 20)

    Participants receiving upadacitinib Dose A with a SALT score \> 20 at Week 52 (end of Period B) of Study 1 or Study 2 will dose escalate to upadacitinib Dose B once daily for 108 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20)

    Participants receiving upadacitinib Dose A with a SALT score ≤ 20 at Week 52 (end of Period B) of Study 1 or Study 2 will remain on upadacitinib Dose A once daily for 108 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3: Group 3 Upadacitinib Dose B (Non-Sustained)

    Participants who end Period B on upadacitinib Dose B with a with a SALT score \> 20 at Week 40 or Week 52 of Study 1 or Study 2 will remain on upadacitinib Dose B once daily for 108 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3: Group 4 Upadacitinib Dose B (Sustained)

    Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose B once daily for 108 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3: Group 5 Upadacitinib Dose A (Sustained)

    Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose A once daily for 108 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 4: Group 1 Upadacitinib Dose A

    US only adolescent participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 4: Group 2 Upadacitinib Dose B

    US only adolescent participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.

    Drug: Upadacitinib

  • Experimental
    Study 4: Group 3 Placebo

    US only adolescent participants will receive matching placebo once daily for 24 weeks in Period A.

    Drug: Placebo

  • Experimental
    Study 4: Group 4 Upadacitinib Dose A

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    Study 4: Group 5 Upadacitinib Dose B

    Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    Study 4: Group 6 Placebo

    Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.

    Drug: Placebo

Interventions

  • Oral Tablets

    Also known as: Rinvoq, ABT-494

  • DrugPlacebo

    Oral Tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Week 24

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 164 weeks

Secondary outcomes

  1. Achievement of SALT score <= 20 for the Comparison of Upadacitinib Dose A QD Versus Placebo

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Week 24

  2. Percentage of Participants with the Achievement of SALT Score <= 10

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Up to Week 24

  3. Percentage of Participants with the Achievement of SALT Score <= 20

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Up to Week 12

  4. Percentage of Participants with the Achievement of Clinician-Reported Outcome (ClinRO) Measure for Eyebrow Hair Loss of 0 or 1

    The ClinRO for Eyebrow Hair Loss is a 4-point response scale where 0 = The eyebrows have full coverage and no areas of hair loss and 3 = No notable eyebrows. Responses should have a ≥ 2-point improvement from Baseline among participants with Baseline score ≥ 2.

    Time frame: Baseline to Week 24

  5. Percentage of Participants with the Achievement of ClinRO Measure for Eyelash Hair Loss of 0 or 1

    The ClinRO for Eyelash Hair Loss is a 4-point response scale where 0 = The eyelashes form a continuous line along the eyelids on both eyes and 3 = No notable eyelashes. Responses should have a ≥ 2-point improvement from Baseline among participants with Baseline score ≥ 2.

    Time frame: Baseline to Week 24

  6. Percentage of Participants with the Achievement of SALT 75

    SALT 75 is defined as at least a 75% improvement \[decrease\] from Baseline in SALT score.

    Time frame: Baseline to Week 24

  7. Percentage of Participants with the Achievement of SALT 90

    SALT 90 is defined as at least a 90% improvement \[decrease\] from Baseline in SALT score.

    Time frame: Baseline to Week 24

  8. Percent Change from Baseline in SALT Score

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Baseline to Week 24

  9. Percentage of Participants with the Achievement of Patients' Global Impression of Change of Alopecia Areata (PaGIC-AA) Score of 1 "Much Better" or 2 "Moderately Better"

    The PaGIC-AA is a single-item measure that asks participants to rate how their alopecia condition has changed overall since the start of the study using a 7-point scale. Responses range from "much better" to "much worse."

    Time frame: Up to Week 24

  10. Percentage of Participants with the Achievement of Patient-Reported Outcome (PRO) for Scalp Hair Assessment 0/1 with ≥ 2-Point Improvement (Reduction)

    The PRO for Scalp Hair Assessment is single item, five-point, categorical response scale that asks respondents to look in the mirror and assess the total area of the scalp with missing hair. Response items range from "No missing hair" to "Nearly all or all" and includes percentage ranges for each category (0%, 1 to 20%, 21 to 49%, 50 to 94%, and 95 to 100%). Responses among participants with baseline score \>=3.

    Time frame: Baseline to Week 24

  11. Change from Baseline in Alopecia Areata Symptom Impact Scale (AASIS) Interference Subscale Score

    The AASIS Interference Subscale is a 6-item assessment with scores ranging from 0 = 'did not interfere' to 10 = 'interfered completely' with higher scores indicating greater symptom interference.

    Time frame: Week 24

  12. Change from Baseline in AASIS Symptoms Subscale Score

    The AASIS Symptom Subscale is a 7-item assessment with scores ranging from 0 = 'not present' to 10 = 'as bad as you can imagine' with higher scores indicating greater symptom severity.

    Time frame: Week 24

  13. Change from Baseline in Skindex-16 AA Emotions Domain Scores

    The Skindex-16 AA Emotions Domain is a 7-item assessment ranging from 0 = never bothered to 6 = always bothered that measures the effects of AA on a subject's health-related quality of life. Higher scores indicate greater impact on health-related quality of life.

    Time frame: Week 24

  14. Change from Baseline in Skindex-16 AA Functioning Domain Scores

    The Skindex-16 AA Emotions Domain is a 5-item assessment ranging from 0 = never bothered to 6 = always bothered, that measures the effects of AA on a subject's health-related quality of life. Higher scores indicate greater impact on health-related quality of life.

    Time frame: Week 24

  15. Achievement of Hospital Anxiety and Depression Scale (HADS)-Anxiety < 8 and HADS-Depression < 8 at Week 24 Among Participants with HADS-A >= 8 or HADS-D >= 8 at Baseline

    The HADS is a self-administered scale which measures anxiety and depression. It contains 14 items and is comprised of anxiety (7 items) and depression (7 items) subscales, which are scored separately and summed to give a total score. Item scores range from 0 (best) to 3 (worst), and total scores are categorized as normal (0 to 7), borderline abnormal (8 to 10), and abnormal (11 to 21).

    Time frame: Baseline to Week 24

  16. Percentage of Participants with the Achievement of SALT Score 0

    The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.

    Time frame: Week 24

07

Study locations

46 of 272 sites recruiting
  • Total Skin and Beauty Dermatology Center /ID# 259539
    Birmingham, Alabama 35205, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Duplicate_Advanced Research Associates - Glendale /ID# 259108
    Glendale, Arizona 85308, United States
    Completed

    Not enrolling at this site — choose another above.

  • Southwest Skin Specialists /ID# 258234
    Phoenix, Arizona 85018-3953, United States
    Completed

    Not enrolling at this site — choose another above.

  • Alliance Dermatology and Mohs Center /ID# 258111
    Phoenix, Arizona 85032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Johnson Dermatology Clinic /ID# 259103
    Fort Smith, Arkansas 72916-6103, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Duplicate_JOSEPH RAOOF MD,INC /ID# 258031
    Encino, California 91436, United States
    Completed

    Not enrolling at this site — choose another above.

  • First Oc Dermatology /ID# 259220
    Fountain Valley, California 92708, United States
    Recruiting
  • University of California Irvine /ID# 259096
    Irvine, California 92697-1385, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dermatology Research Associates /ID# 258033
    Los Angeles, California 90045, United States
    Recruiting
  • Stanford University School of Medicine - Redwood City /ID# 259542
    Redwood City, California 94063, United States
    Completed

    Not enrolling at this site — choose another above.

  • Integrative Skin Science and Research /ID# 258114
    Sacramento, California 95815, United States
    Recruiting
  • University of California Davis Health /ID# 258112
    Sacramento, California 95817, United States
    Recruiting
    • Site Coordinator · Contact916-551-2635
  • Clinical Trials Research Institute /ID# 258021
    Thousand Oaks, California 91320-2130, United States
    Recruiting
  • Skin Care Research Boca Raton /ID# 258012
    Boca Raton, Florida 33486-2269, United States
    Recruiting
    • Site Coordinator · Contact+1-561-948-3116
  • Apex Clinical Trials /ID# 259205
    Brandon, Florida 33511, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Academic Dermatology Center /ID# 259353
    Coral Gables, Florida 33134-5755, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Skin Research Institute LLC /ID# 259207
    Coral Gables, Florida 33146-1837, United States
    Completed

    Not enrolling at this site — choose another above.

  • Revival Research /ID# 259213
    Doral, Florida 33122-1902, United States
    Completed

    Not enrolling at this site — choose another above.

  • Skin Care Research - Hollywood /ID# 259210
    Hollywood, Florida 33021-6748, United States
    Recruiting
    • Site Coordinator · Contact+1-561-948-3116
  • GSI Clinical Research, LLC /ID# 259352
    Margate, Florida 33063, United States
    Recruiting
  • Life Clinical Trials - N State Rd - Margate /ID# 259358
    Margate, Florida 33063, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Lenus Research and Medical Group /ID# 259356
    Miami, Florida 33172, United States
    Recruiting
  • International Clinical Research - Sanford /ID# 259547
    Sanford, Florida 32771, United States
    Completed

    Not enrolling at this site — choose another above.

  • FWD Clinical Research /ID# 266687
    Tamarac, Florida 33321-2931, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Clinical Research Institute - Tampa /ID# 259204
    Tampa, Florida 33607, United States
    Recruiting
    • Site Coordinator · Contact1-813-362-1037
  • Avita Clinical Research /ID# 258011
    Tampa, Florida 33613-1825, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleaver Medical Group Dermatology /ID# 259801
    Dawsonville, Georgia 30534, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Marietta Dermatology /ID# 259818
    Marietta, Georgia 30060, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259555
    Chicago, Illinois 60611, United States
    Completed

    Not enrolling at this site — choose another above.

  • NorthShore University HealthSystem - Skokie /ID# 266684
    Skokie, Illinois 60077, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Indiana University Health University Hospital /ID# 259827
    Indianapolis, Indiana 46202, United States
    Recruiting
  • U.S. Dermatology Partners Leawood /ID# 259203
    Leawood, Kansas 66211-1453, United States
    Completed

    Not enrolling at this site — choose another above.

  • Tulane University School of Medicine /ID# 259799
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Site Coordinator · Contact504-988-5135
  • Raven Clinical Research /ID# 268453
    Marriottsville, Maryland 21104, United States
    Completed

    Not enrolling at this site — choose another above.

  • MetroBoston Clinical Partners /ID# 259559
    Boston, Massachusetts 02135-3511, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Lahey Hospital and Medical Center /ID# 260484
    Burlington, Massachusetts 01805, United States
    Completed

    Not enrolling at this site — choose another above.

  • Great Lakes Research Group - Bay City /ID# 259100
    Bay City, Michigan 48706, United States
    Completed

    Not enrolling at this site — choose another above.

  • Derm Institute of West Michigan /ID# 259546
    Caledonia, Michigan 49316-7478, United States
    Recruiting
    • Site Coordinator · Contact616-512-4445
  • Hamzavi Dermatology - Canton /ID# 260115
    Canton, Michigan 48187, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clarkston Dermatology /ID# 258018
    Clarkston, Michigan 48346, United States
    Recruiting
  • Clinical Research Institute of Michigan /ID# 259802
    Clinton Township, Michigan 48038, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Henry Ford Medical Center - New Center One /ID# 258067
    Detroit, Michigan 48202-3046, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • M Health Fairview University of Minnesota Medical Center - East Bank /ID# 260122
    Minneapolis, Minnesota 55455, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Minnesota Clinical Study Center /ID# 259218
    New Brighton, Minnesota 55112, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dermatology and Skin Center of Lees Summit /ID# 259206
    Lee's Summit, Missouri 64064-2301, United States
    Completed

    Not enrolling at this site — choose another above.

  • Nebraska Dermatology /ID# 259354
    Lincoln, Nebraska 68512, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Skin Specialists /ID# 259237
    Omaha, Nebraska 68144, United States
    Recruiting
    • Site Coordinator · Contact402-697-6599
  • Las Vegas Dermatology /ID# 279317
    Las Vegas, Nevada 89144, United States
    Recruiting
    • Site Coordinator · Contact702 456 3120
  • Skin Cancer and Dermatology Institute - Reno /ID# 259208
    Reno, Nevada 89509, United States
    Recruiting
    • Site Coordinator · Contact775-336-3665
  • The Skin Center Dermatology Group. /ID# 266748
    New City, New York 10956-7153, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Schweiger Dermatology, P.C. /ID# 258007
    New York, New York 07044-2946, United States
    Completed

    Not enrolling at this site — choose another above.

  • Schweiger Dermatology, P.C. /ID# 259531
    New York, New York 07044-2946, United States
    Completed

    Not enrolling at this site — choose another above.

  • Equity Medical /ID# 266680
    New York, New York 10023-7340, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai /ID# 259808
    New York, New York 10029, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sadick Research Group LLC /ID# 266790
    New York, New York 10075, United States
    Recruiting
  • Piedmont Plastic Surgery and Dermatology - Huntersville /ID# 258206
    Huntersville, North Carolina 28078-7961, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleveland Clinic - Cleveland /ID# 258113
    Cleveland, Ohio 44195, United States
    Recruiting
  • Remington-Davis Clinical Research /ID# 258106
    Columbus, Ohio 43215, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dermatologists of Southwest Ohio /ID# 260116
    Mason, Ohio 45040-4520, United States
    Recruiting
    • Site Coordinator · Contact513-701-5526
  • Dermatologist of Central States (DOCS) Clinical Research - Springfield /ID# 266746
    Springfield, Ohio 45505, United States
    Completed

    Not enrolling at this site — choose another above.

  • Oregon Dermatology and Research Center /ID# 258243
    Portland, Oregon 97210, United States
    Recruiting
  • Oregon Medical Research Center /ID# 258107
    Portland, Oregon 97223, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Pittsburgh Medical Center /ID# 266681
    Pittsburgh, Pennsylvania 15213, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical University of South Carolina /ID# 259828
    Charleston, South Carolina 29425, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 278359
    Spartanburg, South Carolina 29307, United States
    Recruiting
    • Site Coordinator · Contact864 574-0017 ext 8
  • Health Concepts /ID# 266678
    Rapid City, South Dakota 57702, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • International Clinical Research - Tennessee LLC /ID# 259552
    Murfreesboro, Tennessee 37130-2450, United States
    Recruiting
  • Arlington Research Center, Inc /ID# 258028
    Arlington, Texas 76011, United States
    Recruiting
  • Bellaire Dermatology Associates /ID# 259360
    Bellaire, Texas 77401, United States
    Recruiting
  • U.S. Dermatology Partners - Cedar Park /ID# 259367
    Cedar Park, Texas 78613, United States
    Recruiting
    • Site Coordinator · Contact512-260-5860
  • Dermatology Treatment and Research Center /ID# 259357
    Dallas, Texas 75230, United States
    Recruiting
  • Modern Research Associates /ID# 259349
    Dallas, Texas 75231, United States
    Completed

    Not enrolling at this site — choose another above.

  • Reveal Research Institute - Dallas /ID# 259361
    Dallas, Texas 75235, United States
    Completed

    Not enrolling at this site — choose another above.

  • Center for Clinical Studies - Houston - Northwest Freeway /ID# 258036
    Houston, Texas 77065, United States
    Completed

    Not enrolling at this site — choose another above.

  • Progressive Clinical Research /ID# 259365
    San Antonio, Texas 78229, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Complete Dermatology /ID# 258025
    Sugar Land, Texas 77479-3794, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dermatology Specialists of Spokane /ID# 278362
    Spokane, Washington 99202, United States
    Recruiting
  • West Virginia University Hospitals /ID# 278707
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Buenos Aires Skin /ID# 258297
    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1055, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Neumonologia y Dermatologia /ID# 258640
    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1425, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Psoriahue Med Interdisciplinar /ID# 258641
    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1425, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ciprec (Centro De Investigacion Y Prevencion Cardiovascular) - Barrio Norte /ID# 258639
    Buenos Aires, 1061, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto De Investigaciones Clinicas Cordoba /ID# 260244
    Córdoba, 5000, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Momentum Clinical Research /ID# 258571
    Darlinghurst, New South Wales 2010, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St George Dermatology & Skin Cancer Centre /ID# 258567
    Kogarah, New South Wales 2217, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cornerstone Dermatology /ID# 258769
    Coorparoo, Queensland 4151, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Veracity Clinical Research /ID# 258566
    Woolloongabba, Queensland 4102, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Skin Health Institute Inc /ID# 258570
    Carlton, Victoria 3053, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sinclair Dermatology - Melbourne /ID# 258565
    East Melbourne, Victoria 3002, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Royal Melbourne Hospital /ID# 258770
    Parkville, Victoria 3050, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fremantle Dermatology /ID# 260207
    Fremantle, Western Australia 6160, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universite Libre de Bruxelles - Hopital Erasme /ID# 257314
    Anderlecht, Brussels Capital 1070, Belgium
    Recruiting
  • Cliniques Universitaires UCL Saint-Luc /ID# 257320
    Brussels, Brussels Capital 1200, Belgium
    Recruiting
  • Universitair Ziekenhuis Brussel /ID# 257325
    Jette, Brussels Capital 1090, Belgium
    Recruiting
  • UZ Gent /ID# 257317
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
  • AZ Delta - campus Torhout /ID# 257321
    Torhout, West-Vlaanderen 8820, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de Liege /ID# 257316
    Liège, 4000, Belgium
    Completed

    Not enrolling at this site — choose another above.

  • Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 258045
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Upeclin Fmb - Unesp /Id# 258046
    Botucatu, São Paulo 18618-686, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital e Maternidade Celso Pierro - PUC-Campinas /ID# 258105
    Campinas, São Paulo 13034-685, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 272 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mostaghimi A, Gooderham MJ, Lynde C, Sinclair R, King B, Hordinsky M, Rudnicka L, Guttman-Yassky E, Serrao R, Ohyama M, Zhang X, Magnolo N, Kwon O, Oddi C, Meerwein S, Soliman AM, Bu X, Duan C, Wu T, Teixeira HD, Lazar A, Passeron T. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials. JAMA Dermatol. 2026 Aug 12:e262853. doi: 10.1001/jamadermatol.2026.2853. Online ahead of print. PubMed 42584887 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2030, 78 months after the start.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Aug 25, 2023
StartActual
Oct 11, 2023
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 23 sites removed. Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 257519 is now Completed
Show 12 added (6 United States, 2 Slovakia, 1 Germany, 1 Poland, 1 China, 1 Italy)
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259555 · Chicago, United States
  • Lahey Hospital and Medical Center /ID# 260484 · Burlington, United States
  • Clinical Research Institute of Michigan /ID# 259802 · Clinton Township, United States
  • Nebraska Dermatology /ID# 259354 · Lincoln, United States
  • The Skin Center Dermatology Group. /ID# 266748 · New City, United States
  • Dermatologists of Southwest Ohio /ID# 260116 · Mason, United States
  • Universitaetsklinikum Muenster - Von-Esmarch-Strasse /ID# 257306 · Münster, Germany
  • Penta Hospitals Badania Kliniczne /ID# 257535 · Wroclaw, Poland
  • Fakultna Nemocnica J.A. Reimana /ID# 257593 · Prešov, Slovakia
  • Affiliated Dermatology Hospital of Shandong First Medical University /ID# 267520 · Jinan, China
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli - Miraglia /ID# 258585 · Naples, Italy
  • Derma therapy /ID# 257595 · Bratislava, Slovakia
Show 23 removed
  • Exalt Clinical Research /ID# 283814 · Chula Vista, United States
  • Georgia Skin & Cancer Clinic /ID# 283529 · Savannah, United States
  • Northwestern University Feinberg School of Medicine /ID# 259555 · Chicago, United States
  • Lahey Hospital & Medical Center /ID# 260484 · Burlington, United States
  • Clin Res Inst of Michigan, LLC /ID# 259802 · Chesterfield, United States
  • Dermatology Associates of West Michigan /ID# 283825 · Grand Rapids, United States
  • Red River Research Partners /ID# 283823 · Lee's Summit, United States
  • Physician Research Collaboration, LLC /ID# 259354 · Lincoln, United States
  • The Skin Center Dermatology Group /ID# 266748 · New City, United States
  • Revival Research Institute - Cary /ID# 283819 · Cary, United States
  • Dermatologists of Southwest Ohio, Inc /ID# 260116 · Mason, United States
  • Dfw Clinical Trials /ID# 284604 · Carrollton, United States
  • Red River Research Partners /ID# 283820 · Houston, United States
  • Harrison Institute for Clinical Research /ID# 283811 · Missouri City, United States
  • San Antonio Clinical Trials /ID# 284605 · San Antonio, United States
  • Medical College Of Wisconsin - Milwaukee Campus /ID# 284590 · Milwaukee, United States
  • Wisconsin Medical Center /ID# 278356 · Milwaukee, United States
  • Universitaetsklinikum Muenster /ID# 257306 · Münster, Germany
  • Penta Hospitals Badania Kliniczne /ID# 257535 · Wroclaw, Poland
  • Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 257593 · Prešov, Slovakia
  • Shandong Dermatological Hospital /ID# 267520 · Jinan, China
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 258585 · Naples, Italy
  • Derma therapy spol /ID# 257595 · Bratislava, Slovakia
across 2 updates, Oct 13, 2026 – Oct 19, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42584887 ↗
Oct 13, 2026
Show all 2 updates
  1. Oct 19, 2026
    3 sites added, 3 sites removed
    Show 3 added (1 China, 1 Italy, 1 Slovakia)
    • Affiliated Dermatology Hospital of Shandong First Medical University /ID# 267520 · Jinan, China
    • Azienda Ospedaliera Universitaria Luigi Vanvitelli - Miraglia /ID# 258585 · Naples, Italy
    • Derma therapy /ID# 257595 · Bratislava, Slovakia
    Show 3 removed
    • Shandong Dermatological Hospital /ID# 267520 · Jinan, China
    • Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 258585 · Naples, Italy
    • Derma therapy spol /ID# 257595 · Bratislava, Slovakia
  2. Oct 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42584887 ↗
    9 sites added, 20 sites removed. Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 257519 is now Completed
    Show 9 added (6 United States, 1 Germany, 1 Poland, 1 Slovakia)
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259555 · Chicago, United States
    • Lahey Hospital and Medical Center /ID# 260484 · Burlington, United States
    • Clinical Research Institute of Michigan /ID# 259802 · Clinton Township, United States
    • Nebraska Dermatology /ID# 259354 · Lincoln, United States
    • The Skin Center Dermatology Group. /ID# 266748 · New City, United States
    • Dermatologists of Southwest Ohio /ID# 260116 · Mason, United States
    • Universitaetsklinikum Muenster - Von-Esmarch-Strasse /ID# 257306 · Münster, Germany
    • Penta Hospitals Badania Kliniczne /ID# 257535 · Wroclaw, Poland
    • Fakultna Nemocnica J.A. Reimana /ID# 257593 · Prešov, Slovakia
    Show 20 removed
    • Exalt Clinical Research /ID# 283814 · Chula Vista, United States
    • Georgia Skin & Cancer Clinic /ID# 283529 · Savannah, United States
    • Northwestern University Feinberg School of Medicine /ID# 259555 · Chicago, United States
    • Lahey Hospital & Medical Center /ID# 260484 · Burlington, United States
    • Clin Res Inst of Michigan, LLC /ID# 259802 · Chesterfield, United States
    • Dermatology Associates of West Michigan /ID# 283825 · Grand Rapids, United States
    • Red River Research Partners /ID# 283823 · Lee's Summit, United States
    • Physician Research Collaboration, LLC /ID# 259354 · Lincoln, United States
    • The Skin Center Dermatology Group /ID# 266748 · New City, United States
    • Revival Research Institute - Cary /ID# 283819 · Cary, United States
    • Dermatologists of Southwest Ohio, Inc /ID# 260116 · Mason, United States
    • Dfw Clinical Trials /ID# 284604 · Carrollton, United States
    • Red River Research Partners /ID# 283820 · Houston, United States
    • Harrison Institute for Clinical Research /ID# 283811 · Missouri City, United States
    • San Antonio Clinical Trials /ID# 284605 · San Antonio, United States
    • Medical College Of Wisconsin - Milwaukee Campus /ID# 284590 · Milwaukee, United States
    • Wisconsin Medical Center /ID# 278356 · Milwaukee, United States
    • Universitaetsklinikum Muenster /ID# 257306 · Münster, Germany
    • Penta Hospitals Badania Kliniczne /ID# 257535 · Wroclaw, Poland
    • Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 257593 · Prešov, Slovakia
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06012240
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Oct 11, 2023
Primary completion
Apr 2030 (estimated)
Completion
Apr 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion